Navigation Links
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Date:6/1/2009

dels.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "Plans are underway to expand this study and evaluate additional patients with a variety of cancers as well as specifically those with colorectal and ovarian cancers. These additional data will guide our selection of the most promising solid tumor indications for further study in Phase 2. The recent initiation of Phase 1 studies in multiple myeloma and leukemia will allow us to extend the possible indications for ENMD-2076 into hematological malignancies where preclinical data have been encouraging. These data and the initiation of additional studies have added significant value to the program and, in line with the Company's strategy to accelerate the clinical development of ENMD-2076, partnering discussions continue."

To view a copy of the poster and slide presentations, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at www.entremed.com.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the Flt-3 and FGFR3, kinases which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angioge
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Initial Clinical Results for ENMD-2076
2. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
3. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
4. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
7. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. EntreMed to Present at The New York Society of Security Analysts Industry Conference
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... announced today that the company,s board of directors approved a ... June 30. Accordingly, DelMar will file a Transition Form 10K ... Bacha , president and CEO of DelMar stated, "The change ... our goal of obtaining a senior exchange listing for our ...
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
(Date:7/24/2014)... , July 24, 2014 Talyst, a market ... 2014 National Association of State Veterans Homes (NASVH) Summer ... The goal of the NASVH is to ensure that ... services, long term health care and respect which they ... With the InSite® Remote Dispensing System, Talyst can ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Dry Powder ... http://www.reportlinker.com/p0581176/Dry-Powder-Inhalation-Devices-Drugs-Therapeutics-Markets-and-Forecasts ... formulation and inhalation device design are creating ...
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Insulin- Global ... This package contains 63 insulin market ... Bulgaria, Czech Republic,Denmark, Estonia, Finland, France, Germany, ...
Cached Medicine Technology:Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 2Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 3Insulin- Global 2
(Date:7/24/2014)... Doheny HealthDay Reporter THURSDAY, ... often don,t view their kids as unhealthy or recognize the ... new study. The children of the families surveyed for ... Hasbro Children,s Hospital in Providence, R.I. "A third categorized ... researcher Dr. Kyung Rhee, now an assistant professor of pediatrics ...
(Date:7/24/2014)... researchers may have found a way to delay or ... of neurons with the anti-aging protein Klotho can prevent ... protein and glutamate. These findings currently appear in the ... disease is the most frequent age-related dementia affecting 5.4 ... and older and more than 40 percent of people ...
(Date:7/24/2014)... SHAWNEE, Kan. (PRWEB) July 24, 2014 ... announces that it has achieved certification for ... as tested and verified by the DoD Information ... Acuo Vendor Neutral Archive, identified within the DoD ... the Authority to Operate designation from the U.S. ...
(Date:7/24/2014)... equally positive outcomes experience paradoxical feelings of pleasure ... regions of the brain, according to research led ... the Princeton Neuroscience Institute at Princeton University. ... desirability of more than 300 products using an ... paired products with different or similar values and ...
(Date:7/24/2014)... 2014 Horizon BCBSNJ’s second annual “Back ... family a rent-free week in a beautiful Lavallette shore ... Don’t miss your chance to win a week’s vacation ... all New Jersey residents, 25 or older.* Residents can ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at the ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... healthcare grade televisions and on-demand patient and staff interactive education ... education and entertainment system into Timpanogos Regional Hospital in Orem, ... ... Raleigh, NC (Vocus) May 20, 2009 -- TeleHealth Services ...
... and nerve damage , , WEDNESDAY, May 20 (HealthDay News) -- ... their blood glucose levels at a normal, low level. ... when it comes to avoiding the complications of the disease, ... Diabetes is a disease in which the body does not ...
... Minn., May 20 Orasi Medical, Inc. announced today ... financing round.The company will use this capital to expand ... the pharmaceutical and clinical markets. Pharmaceutical companies will use ... to treat various neurological diseases. Orasi is currently in ...
... Side discrepancy errors in radiology reports do occur and ... communicate well to help prevent errors in clinical management, ... Boston, MA. "Side discrepancy errors refer to instances when ... one or more sections of the radiology report," said ...
... Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports ... of some significant new advances recently announced regarding the ... are currently conducting research. , On Wednesday, May 13, ... A ground-breaking Canada-wide clinical ...
... St. Cloud Orthopedic Associates (SCOA), the largest orthopedic physician ... chosen to partner with the St. Cloud Surgical Center, ... a group of local physicians. SCA is a leading ... allow St. Cloud Surgical Center, which has provided high ...
Cached Medicine News:Health News:TeleHealth Services chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 2Health News:TeleHealth Services chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 3Health News:TeleHealth Services chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 4Health News:Glucose Control Pays Long-Term Benefits for Diabetics 2Health News:Hard to Treat Diseases, Inc. (HTDS) Reports on New Uses For Ribavirin 2Health News:Hard to Treat Diseases, Inc. (HTDS) Reports on New Uses For Ribavirin 3Health News:St. Cloud Orthopedic Associates to Partner with Surgical Care Affiliates 2
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
... design allows the ureter to be dilated ... at the base of the balloon allows ... dilation. Supplied sterile in peel-open packages. Intended ... Handle (plastic), Straight Safety Wire Guide [.038 ...
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
Medicine Products: